Option chain shows key data for Galecto's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Galecto.

Galecto (NASDAQ:GLTO) Stock, Option Chain

Galecto

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

stock-market-6693060

News

GLTO

Galecto shares are trading lower by 27% during Monday&#39;s session. The company issued 62,594 common and 160,562 preferred convertible shares to Bridge Medicine for BRM-1420 acquisition rights.

Why Galecto (GLTO) Shares Are Down 27% Today

Earnings

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

RKLB

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Nike, AAR And 3 Stocks To Watch Heading Into Friday

Small Cap

Intraday Update

Movers

ADES

AONC

APLS

AVGR

AXLA

BHVN

COOK

CRDF

FEMY

FENG

FFIE

IMVT

INPX

LIFW

MCLD

METC

MLKN

PIXY

PYPD

RNAZ

SLNO

SOUN

SPRC

STSS

THAR

UTRS

VBIV

VINO

XWEL

Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Galecto Inc

Press Releases

Galecto Announces Reverse Stock Split

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Management

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Galecto Reports Third Quarter 2024 Financial Results

Galecto to Participate in Upcoming Investor Conferences

Galecto Reports Full-Year 2024 Financial Results

Galecto Reports First Quarter 2025 Operating and Financial Results

Aptevo Therapeutics

180 Life Sciences

Azitra

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Palisade Bio

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Oppenheimer

SVB Leerink

Cantor Fitzgerald

Credit Suisse

Comments

Galecto

Galecto (GLTO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell